147 related articles for article (PubMed ID: 2987573)
1. [Mechanisms of antiherpes drugs and drug resistant virus--effect of BVDU on varicella zoster virus replication].
Shigeta S; Yokota T
Rinsho Byori; 1985 Feb; 33(2):148-57. PubMed ID: 2987573
[No Abstract] [Full Text] [Related]
2. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
3. Interactions between virus and antiviral compounds in the host cell.
Harmenberg J
Med Biol; 1984; 62(6):299-303. PubMed ID: 6099858
[No Abstract] [Full Text] [Related]
4. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958
[TBL] [Abstract][Full Text] [Related]
5. [Antiviral resistance of herpes simplex virus and varicella-zoster virus].
Daikoku T; Shiraki K
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():480-6. PubMed ID: 17455667
[No Abstract] [Full Text] [Related]
6. Thymidine kinase with altered substrate specificity of acyclovir resistant varicella-zoster virus.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1986 Mar; 29(1):7-10. PubMed ID: 3022711
[TBL] [Abstract][Full Text] [Related]
7. Therapy of varicella-zoster virus infection--mechanism of action of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Shigeta S; Yokota T; De Clercq E
Antiviral Res; 1985; Suppl 1():35-44. PubMed ID: 3002264
[No Abstract] [Full Text] [Related]
8. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
Yokota T; Konno K; Shigeta S; Verbruggen A; De Clercq E
Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
[TBL] [Abstract][Full Text] [Related]
9. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].
Morfin F; Frobert E; Thouvenot D
Ann Biol Clin (Paris); 2003; 61(1):33-40. PubMed ID: 12604384
[TBL] [Abstract][Full Text] [Related]
12. Susceptibilities of phosphonoacetic acid and acyclovir resistant varicella-zoster virus mutants to 9-beta-arabinofuranosyladenine and 1-beta-arabinofuranosylcytosine.
Shiraki K; Ogino T; Yamamoto T; Yamanishi K; Takahashi M
Biken J; 1986 Mar; 29(1):11-7. PubMed ID: 3022709
[TBL] [Abstract][Full Text] [Related]
13. [Combined action of nucleosides and alpha-interferon in inhibiting the reproduction of the herpes simplex type-II virus].
Temicheva EV; Malinovskaia VV; Manakhova LS; Mironova LL; Galegov GA
Biull Eksp Biol Med; 1987 Oct; 104(10):490-2. PubMed ID: 2823929
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
Bleymehl K; Cinatl J; Schmidt-Chanasit J
Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Suzuki M; Okuda T; Shiraki K
Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
[TBL] [Abstract][Full Text] [Related]
17. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
18. Viral sensitivity following the introduction of acyclovir.
Collins P
Am J Med; 1988 Aug; 85(2A):129-34. PubMed ID: 2841855
[TBL] [Abstract][Full Text] [Related]
19. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.
Hatchette T; Tipples GA; Peters G; Alsuwaidi A; Zhou J; Mailman TL
Pediatr Infect Dis J; 2008 Jan; 27(1):75-7. PubMed ID: 18162946
[TBL] [Abstract][Full Text] [Related]
20. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
Yokota T; Konno K; Shigeta S; De Clercq E
Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
